60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
60 Degrees Pharmaceuticals signed an exclusive patent license with Florida State University to extract castanospermine from Australian Chestnut seeds for non-prescription use. The company will meet with the FDA on July 1, 2026, to discuss feedback on its New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract.
Key figures
- Fda meeting date
- July 1, 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.